Is STTK or LONA more profitable?

Shattuck Labs' return on equity of -60.73% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -60.73% -55.75% Athira Pharma N/A -381.01% -225.74%

Is PRLD or LONA more profitable?

Prelude Therapeutics' return on equity of -118.24% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% Athira Pharma N/A -381.01% -225.74%

Do analysts rate SIGA or LONA?

Athira Pharma has a consensus target price of $15.00, indicating a potential upside of 75.85%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Siga Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Athira Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has higher valuation & earnings, LONA or AMRN?

Amarin has higher revenue and earnings than Athira Pharma. Amarin is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Athira Pharma N/A N/A -$105.61M -$5.21 N/A Amarin $213.65M 1.50 -$38.80M -$0.65 N/A

Is LONA or AMRN more profitable?

Athira Pharma has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Athira Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Athira Pharma N/A -381.01% -225.74% Amarin -15.51% -2.99% -2.07%

Athira Pharma (LONA) Competitors

$8.53 +0.18 (+2.16%)

As of 10:46 AM Eastern

Compare

LONA vs. STTK, PRLD, SIGA, AMRN, and LYEL

Should you buy Athira Pharma stock or one of its competitors? MarketBeat compares Athira Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Athira Pharma include Shattuck Labs (STTK), Prelude Therapeutics (PRLD), Siga Technologies (SIGA), Amarin (AMRN), and Lyell Immunopharma (LYEL). These companies are all part of the "pharmaceutical products" industry.

How does Athira Pharma compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Shattuck Labs' return on equity of -60.73% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-60.73%	-55.75%
Athira Pharma	N/A	-381.01%	-225.74%

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by company insiders. Comparatively, 25.7% of Athira Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Shattuck Labs has a beta of 1.08, suggesting that its stock price is 8% more volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market.

Shattuck Labs currently has a consensus price target of $11.00, suggesting a potential upside of 133.89%. Athira Pharma has a consensus price target of $15.00, suggesting a potential upside of 75.85%. Given Shattuck Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe Shattuck Labs is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Shattuck Labs has higher revenue and earnings than Athira Pharma. Shattuck Labs is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	360.63	-$48.81M	-$0.63	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

In the previous week, Shattuck Labs had 16 more articles in the media than Athira Pharma. MarketBeat recorded 17 mentions for Shattuck Labs and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Shattuck Labs' score of 0.52 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Shattuck Labs	Positive
Athira Pharma	Very Positive

Summary

Shattuck Labs beats Athira Pharma on 10 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

Prelude Therapeutics' return on equity of -118.24% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
Athira Pharma	N/A	-381.01%	-225.74%

Prelude Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Athira Pharma has a beta of 1.97, suggesting that its stock price is 97% more volatile than the broader market.

79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 57.1% of Athira Pharma shares are held by institutional investors. 49.2% of Prelude Therapeutics shares are held by company insiders. Comparatively, 25.7% of Athira Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Prelude Therapeutics has higher revenue and earnings than Athira Pharma. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$12.14M	29.91	-$99.50M	-$1.00	N/A
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

In the previous week, Prelude Therapeutics had 1 more articles in the media than Athira Pharma. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Prelude Therapeutics' score of 0.94 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Prelude Therapeutics	Positive
Athira Pharma	Very Positive

Prelude Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 68.17%. Athira Pharma has a consensus price target of $15.00, suggesting a potential upside of 75.85%. Given Athira Pharma's higher possible upside, analysts plainly believe Athira Pharma is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Prelude Therapeutics beats Athira Pharma on 8 of the 12 factors compared between the two stocks.

How does Athira Pharma compare to Siga Technologies?

Siga Technologies (NASDAQ:SIGA) and Athira Pharma (NASDAQ:LONA) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

Siga Technologies has higher revenue and earnings than Athira Pharma. Athira Pharma is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57M	3.26	$23.28M	$0.27	15.94
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A

Siga Technologies has a net margin of 21.58% compared to Athira Pharma's net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Siga Technologies	21.58%	10.60%	8.94%
Athira Pharma	N/A	-381.01%	-225.74%

55.4% of Siga Technologies shares are owned by institutional investors. Comparatively, 57.1% of Athira Pharma shares are owned by institutional investors. 2.7% of Siga Technologies shares are owned by insiders. Comparatively, 25.7% of Athira Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Athira Pharma has a consensus target price of $15.00, indicating a potential upside of 75.85%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Athira Pharma is more favorable than Siga Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Siga Technologies and Siga Technologies both had 1 articles in the media. Athira Pharma's average media sentiment score of 1.89 beat Siga Technologies' score of 1.87 indicating that Athira Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Siga Technologies	Very Positive
Athira Pharma	Very Positive

Siga Technologies has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Athira Pharma has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market.

Summary

Siga Technologies and Athira Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Athira Pharma compare to Amarin?

Athira Pharma (NASDAQ:LONA) and Amarin (NASDAQ:AMRN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Athira Pharma currently has a consensus price target of $15.00, suggesting a potential upside of 75.85%. Amarin has a consensus price target of $12.00, suggesting a potential downside of 21.59%. Given Athira Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Athira Pharma is more favorable than Amarin.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Amarin	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

In the previous week, Amarin had 2 more articles in the media than Athira Pharma. MarketBeat recorded 3 mentions for Amarin and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Amarin's score of 0.89 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Very Positive
Amarin	Positive

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 22.3% of Amarin shares are held by institutional investors. 25.7% of Athira Pharma shares are held by insiders. Comparatively, 4.2% of Amarin shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Athira Pharma has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market. Comparatively, Amarin has a beta of 0.82, meaning that its stock price is 18% less volatile than the broader market.

Amarin has higher revenue and earnings than Athira Pharma. Amarin is trading at a lower price-to-earnings ratio than Athira Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Amarin	$213.65M	1.50	-$38.80M	-$0.65	N/A

Athira Pharma has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Amarin	-15.51%	-2.99%	-2.07%

Summary

Athira Pharma beats Amarin on 9 of the 15 factors compared between the two stocks.

How does Athira Pharma compare to Lyell Immunopharma?

Athira Pharma (NASDAQ:LONA) and Lyell Immunopharma (NASDAQ:LYEL) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

Athira Pharma has higher earnings, but lower revenue than Lyell Immunopharma. Athira Pharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Athira Pharma	N/A	N/A	-$105.61M	-$5.21	N/A
Lyell Immunopharma	$31K	10,142.76	-$274.45M	-$13.80	N/A

In the previous week, Lyell Immunopharma had 11 more articles in the media than Athira Pharma. MarketBeat recorded 12 mentions for Lyell Immunopharma and 1 mentions for Athira Pharma. Athira Pharma's average media sentiment score of 1.89 beat Lyell Immunopharma's score of 0.75 indicating that Athira Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Athira Pharma	Very Positive
Lyell Immunopharma	Positive

Athira Pharma has a beta of 1.97, indicating that its share price is 97% more volatile than the broader market. Comparatively, Lyell Immunopharma has a beta of -0.09, indicating that its share price is 109% less volatile than the broader market.

Athira Pharma presently has a consensus target price of $15.00, suggesting a potential upside of 75.85%. Lyell Immunopharma has a consensus target price of $43.00, suggesting a potential upside of 219.11%. Given Lyell Immunopharma's stronger consensus rating and higher probable upside, analysts clearly believe Lyell Immunopharma is more favorable than Athira Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Athira Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Lyell Immunopharma	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

57.1% of Athira Pharma shares are held by institutional investors. Comparatively, 66.1% of Lyell Immunopharma shares are held by institutional investors. 25.7% of Athira Pharma shares are held by company insiders. Comparatively, 6.2% of Lyell Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Athira Pharma has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -794,858.12%. Lyell Immunopharma's return on equity of -85.71% beat Athira Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Athira Pharma	N/A	-381.01%	-225.74%
Lyell Immunopharma	-794,858.12%	-85.71%	-66.41%

Summary

Lyell Immunopharma beats Athira Pharma on 10 of the 16 factors compared between the two stocks.

Get Athira Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LONA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LONA vs. The Competition

Export

Metric	Athira Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$80.41M	$423.94M	$4.35B	$12.31B
Dividend Yield	N/A	N/A	10.25%	5.66%
P/E Ratio	-1.64	N/A	22.33	24.76
Price / Sales	N/A	332.46	130.36	168.32
Price / Cash	N/A	N/A	40.19	37.92
Price / Book	2.86	2.59	27.52	6.90
Net Income	-$105.61M	-$81.71M	$116.61M	$337.45M
7 Day Performance	-0.70%	2.33%	2.54%	2.84%
1 Month Performance	-24.25%	-9.49%	2.67%	4.78%
1 Year Performance	N/A	N/A	15.22%	33.08%

Athira Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LONA Athira Pharma	3.9238 of 5 stars	$8.53 +2.2%	$15.00 +75.8%	N/A	$80.41M	N/A	N/A	40	Positive News
STTK Shattuck Labs	4.4602 of 5 stars	$4.18 +1.2%	$11.00 +163.2%	+389.1%	$316.69M	$1M	N/A	100	Analyst Upgrade Gap Down
PRLD Prelude Therapeutics	4.0714 of 5 stars	$4.11 +4.1%	$7.67 +86.5%	+367.7%	$314.60M	$12.14M	N/A	120
SIGA Siga Technologies	0.5718 of 5 stars	$4.31 -1.1%	N/A	-32.1%	$312.72M	$94.57M	15.96	40	Positive News
AMRN Amarin	0.4795 of 5 stars	$14.90 +0.9%	$12.00 -19.5%	+15.0%	$309.50M	$213.65M	N/A	360

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LONA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Athira Pharma (LONA) Competitors

LONA vs. STTK, PRLD, SIGA, AMRN, and LYEL

How does Athira Pharma compare to Shattuck Labs?

Summary

How does Athira Pharma compare to Prelude Therapeutics?

Summary

How does Athira Pharma compare to Siga Technologies?

Summary

How does Athira Pharma compare to Amarin?

Summary

How does Athira Pharma compare to Lyell Immunopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Athira Pharma (LONA) Competitors

LONA vs. STTK, PRLD, SIGA, AMRN, and LYEL

How does Athira Pharma compare to Shattuck Labs?

Is STTK or LONA more profitable?

Do institutionals and insiders have more ownership in STTK or LONA?

Which has more volatility and risk, STTK or LONA?

Do analysts recommend STTK or LONA?

Which has stronger earnings and valuation, STTK or LONA?

Does the media refer more to STTK or LONA?

Summary

How does Athira Pharma compare to Prelude Therapeutics?

Is PRLD or LONA more profitable?

Which has more volatility and risk, PRLD or LONA?

Do insiders & institutionals hold more shares of PRLD or LONA?

Which has higher valuation and earnings, PRLD or LONA?

Does the media refer more to PRLD or LONA?

Do analysts rate PRLD or LONA?

Summary

How does Athira Pharma compare to Siga Technologies?

Which has higher valuation and earnings, SIGA or LONA?

Is SIGA or LONA more profitable?

Do insiders and institutionals have more ownership in SIGA or LONA?

Do analysts rate SIGA or LONA?

Does the media favor SIGA or LONA?

Which has more risk & volatility, SIGA or LONA?

Summary

How does Athira Pharma compare to Amarin?

Do analysts prefer LONA or AMRN?

Does the media refer more to LONA or AMRN?

Do institutionals & insiders hold more shares of LONA or AMRN?

Which has more risk and volatility, LONA or AMRN?

Which has higher valuation & earnings, LONA or AMRN?

Is LONA or AMRN more profitable?

Summary

How does Athira Pharma compare to Lyell Immunopharma?

Which has preferable earnings and valuation, LONA or LYEL?

Does the media prefer LONA or LYEL?

Which has more risk & volatility, LONA or LYEL?

Do analysts prefer LONA or LYEL?

Do insiders & institutionals hold more shares of LONA or LYEL?

Is LONA or LYEL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LONA vs. The Competition

Athira Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools